Kyle Bass’s success rate at the PTAB – an update | Managing Intellectual Property
`
`Page 1 of 6
`
`Region:
`
`Welcome: Ellie Yost My Clippings My Searches My Account Logout
`
`Blog
`
`
`
`KYLE BASS’S SUCCESS RATE AT THE PTAB – AN UPDATE
`
`22 December 2015 |
`Michael Loney
`
`Hedge fund manager Kyle Bass has not gotten any
`holiday cheer from the Patent Trial and Appeal Board,
`with two of his petitions challenging pharmaceutical
`patents denied this month. The Board has now ruled on
`16 of his inter partes review petitions
`
`December has not been kind to hedge
`fund manager Kyle Bass’s efforts to
`invalidate pharmaceutical patents
`through Patent Trial and Appeal Board
`proceedings.
`
`The Board this month has denied
`institution of two of his inter partes
`review petitions. Its decisions on
`December 8 and 17 both involved
`patents covering Pozen’s Vimovo
`arthritis pain treatment, which is
`marketed in the US by Horizon Pharma.
`
`For those keeping score, the PTAB has now given an institution decision
`in 16 of the 33 petitions filed by the Coalition for Affordable Drugs, the
`coalition set up by Bass and Erich Spangenberg to attack pharma patents.
`
`http://www.managingip.com/Blog/3516275/Kyle-Basss-success-rate-at-the-PTABan-updat...
`
`3/10/2016
`
`Fresenius Ex. 2023
`Bass et al. v. Fresenius Kabi USA, IPR2016-00254
`
`

`

`Kyle Bass’s success rate at the PTAB – an update | Managing Intellectual Property
`
`Page 2 of 6
`
`This means the board has now given an institution decision on almost half
`of the Coalition for Affordable Drugs petitions (see table below).
`
`Bass’s success rate for institution now stands at
`44%, with the PTAB instituting trial for seven
`IPRs and denying nine. This is down from the
`heady days of October, when Bass could boast a
`54% rate of success after the Board had
`instituted seven of the 13 petitions it had
`decided up until then.
`
`The Board has denied three petitions in a row
`since then.
`
`Bass will be hoping to break this losing streak
`next month when the Board is likely to give
`more decisions, including on two more IPRs
`challenging the Vimovo treatment.
`
`The PTAB has given decisions on all of Bass’s petitions filed until the end
`of June. Next up it must decide on the 12 petitions the Coalition filed in
`August and the five petitions filed in September.
`
`Interestingly, Bass and Spangenberg in November also filed two petitions
`with just their two names listed, and no Coalition for Affordable Drugs.
`These petitions challenged patents owned by Alpex Pharma and
`Fresenius.
`
`The Coalition for Affordable Drugs' IPR petitions*
`
`IPR
`
`Date filed Law firm used by
`
`Patent
`
`Patent owner
`
`number
`
`the Coalition
`
`number
`
`
`
`IPR2015-
`
`February
`
`Skiermont Puckett
`
`8,663,685 Acorda Therapeutics
`
`00720
`
`10
`
`IPR2015-
`
`February
`
`Skiermont Puckett
`
`8,007,826 Acorda Therapeutics
`
`00817
`
`27
`
`IPR2015-
`
`April 1
`
`Skiermont Puckett
`
`6,773,720 Cosmo
`
`00988
`
`Technologies/Nogra
`Pharma/Shire
`
`Development/Shire
`
`Inc/Shire Pharmaceuticsl
`Development
`
`IPR2015-
`
`April 1 Merchant & Gould
`
`7,056,886 NPS
`
`00990
`
`Pharmaceuticals/Shire
`
`North American Group
`
`IPR2015-
`
`April 6 Merchant & Gould
`
`7,895,059 Jazz Pharmaceuticals
`
`01018
`
`IPR2015-
`
`April 20 Merchant & Gould
`
`8,754,090 Pharmacyclics
`
`01076
`
`
`
`
`
`
`http://www.managingip.com/Blog/3516275/Kyle-Basss-success-rate-at-the-PTABan-updat...
`
`3/10/2016
`
`Fresenius Ex. 2023
`Bass et al. v. Fresenius Kabi USA, IPR2016-00254
`
`

`

`Kyle Bass’s success rate at the PTAB – an update | Managing Intellectual Property
`
`Page 3 of 6
`
`IPR2015-
`01086
`
`April 22 Neifeld IP Law
`
`8,759,393 Biogen International
`
`
`
`IPR2015-
`
`April 23
`
`Skiermont Puckett
`
`6,315,720 Celgene Corporation
`
`01102
`
`IPR2015-
`
`April 23
`
`Skiermont Puckett
`
`6,315,720 Celgene Corporation
`
`01096
`
`IPR2015-
`
`April 23
`
`Skiermont Puckett
`
`6,315,720 Celgene Corporation
`
`01103
`
`IPR2015-
`
`April 23
`
`Skiermont Puckett
`
`6,045,501 Celgene Corporation
`
`01092
`
`IPR2015-
`
`April 23 Merchant & Gould
`
`7,056,886 NPS
`
`01093
`
`Pharmaceuticals/Shire
`
`North American Group
`
`IPR2015-
`
`May 1
`
`Neifeld IP Law
`
`8,399,514 Biogen MA
`
`01136
`
`IPR2015-
`01169
`
`May 7
`
`Merchant & Gould
`
`5,635,517 Celgene Corporation
`
`IPR2015-
`
`May 21
`
`Conley Rose
`
`6,926,907 Pozen (Horizon Pharma
`
`01241
`
`bought the rights to the
`
`drug in November
`2013))
`
`IPR2015-
`
`June 5
`
`Conley Rose
`
`8,858,996 Horizon Pharma/Pozen
`
`01344
`
`IPR2015-
`
`August 7 Conley Rose
`
`8,852,636 Pozen (Horizon Pharma
`
`01680
`
`bought the rights to the
`
`drug in November
`
`2013))
`
`IPR2015-
`
`August 12 Conley Rose
`
`8,945,621 Horizon Pharma/Pozen
`
`01718
`
`IPR2015-
`01723
`
`August 13 Cunningham
`Swaim/Winstead
`
`6,967,208 Bristol Myers Squibb
`Pharma
`
`IPR2015-
`
`August 20 Merchant & Gould
`
` 7,582,621 Anacor/Sandoz
`
`01776
`
`IPR2015-
`01785
`
`August 20 Merchant & Gould
`
`7,767,657 Anacor/Sandoz
`
`IPR2015-
`
`August 20 Merchant & Gould
`
`7,767,657 Anacor/Sandoz
`
`01780
`
`IPR2015-
`
`August 22 Neifeld IP Law
`
`8,163,522 Amgen/Hoffmann-La
`
`01792
`
`Roche/Immunex
`
`IPR2015-
`
`August 24 Law Offices of
`
`8,835,460 Insys Pharma
`
`01799
`
`
`
`Gregory J
`
`
`
`
`
`http://www.managingip.com/Blog/3516275/Kyle-Basss-success-rate-at-the-PTABan-updat...
`
`3/10/2016
`
`Fresenius Ex. 2023
`Bass et al. v. Fresenius Kabi USA, IPR2016-00254
`
`

`

`Kyle Bass’s success rate at the PTAB – an update | Managing Intellectual Property
`
`Page 4 of 6
`
`Gonsalves/McNeeley
`Hare & War
`
`IPR2015-
`
`August 24 Law Offices of
`
`8,835,459 Insys Pharma
`
`01797
`
`Gregory J
`Gonsalves/McNeeley
`
`Hare & War
`
`IPR2015-
`
`August 24 Law Offices of
`
`8,486,972 Insys Pharma
`
`01800
`
`Gregory J
`Gonsalves/McNeeley
`
`Hare & War
`
`IPR2015-
`01835
`
`August 28 Law Offices of
`Gregory J
`
`8,618,135 Aegerion
`Pharmaceuticals/Trustees
`
`Juxtapid
`
`Gonsalves/McNeeley
`
`of The University of
`
`Hare & War
`
`Pennsylvania
`
`IPR2015-
`01836
`
`August 28 Law Offices of
`Gregory J
`
`7,932,268 Aegerion
`Pharmaceuticals/Trustees
`
`Juxtapid
`
`Gonsalves/McNeeley
`
`of The University of
`
`Hare & War
`
`Pennsylvania
`
`IPR2015-
`
`September
`
`Skiermont Puckett
`
`8,440,703 Acorda Therapeutics
`
`Ampyra
`
`01850
`
`2
`
`IPR2015-
`
`September
`
`Skiermont Puckett
`
`8,007,826 Acorda Therapeutics
`
`Ampyra
`
`01853
`
`2
`
`IPR2015-
`
`September
`
`Skiermont Puckett
`
`8,354,437 Acorda Therapeutics
`
`Ampyra
`
`01858
`
`3
`
`IPR2015-
`01857
`
`September
`3
`
`Skiermont Puckett
`
`8,663,685 Acorda Therapeutics
`
`Ampyra
`
`IPR2015-
`
`September
`
`Neifeld IP Law
`
`8,399,514 Biogen MA
`
`Tecfidera
`
`01993
`
`28
`
`All of the IPRs list the petitioners as the Coalition for Affordable Drugs, J Kyle Bass, Erich
`
`Spangenberg, Hayman Capital Management, various Hayman funds, IP Navigation Group, and
`
`nXn Partners
`
`Source: Docket Navigator
`
`
`
`
`IPR petitions filed listing only Kyle Bass and Erich Spangenberg
`
`IPR
`
`Date filed Law firm used
`
`Patent
`
`Patent
`
`Drug
`
`number
`
`number
`
`owner
`
`used in
`
`IPR2016-
`00245
`
`November
`24
`
`Law Offices of Gregory J
`Gonsalves/McNeeley
`
`8,440,170 Alpex
`Pharma
`
`Suprenza
`
`Hare & War
`
`IPR2016-
`00254
`
`November
`25
`
`Law Offices of Gregory J
`Gonsalves/McNeeley
`
`8,476,010 Fresenius
`Kabi
`
`Diprivan
`
`Hare & War
`
`Source: Docket Navigator
`
`
`
`
`http://www.managingip.com/Blog/3516275/Kyle-Basss-success-rate-at-the-PTABan-updat...
`
`3/10/2016
`
`Fresenius Ex. 2023
`Bass et al. v. Fresenius Kabi USA, IPR2016-00254
`
`

`

`Kyle Bass’s success rate at the PTAB – an update | Managing Intellectual Property
`
`Page 5 of 6
`
`Only 30% of Managing IP content is published on the blog – to access
`all of our content you need to be a subscriber.
`
`We like to offer our loyal blog readers a special rate, so simply fill in this
`form in to qualify and we will be in contact to discuss your subscription
`options.
`
`COMMENTS
`
`Ellie Yost
`
`Display this name
`
` 
`
`
`
`eyost@goodwinprocter.com
`
`Please enter a comment here... Please note
`comments are subject to editorial review.
`
`Type the text
`
`Privacy & Terms
`
`
`
`Notify me of follow up comments
`
`
`
`
`
`http://www.managingip.com/Blog/3516275/Kyle-Basss-success-rate-at-the-PTABan-updat...
`
`3/10/2016
`
`Fresenius Ex. 2023
`Bass et al. v. Fresenius Kabi USA, IPR2016-00254
`
`
`
`

`

`Kyle Bass’s success rate at the PTAB – an update | Managing Intellectual Property
`
`Page 6 of 6
`
`THE MATERIAL ON THIS SITE IS FOR FINANCIAL INSTITUTIONS, PROFESSIONAL INVESTORS AND
`THEIR PROFESSIONAL ADVISERS. IT IS FOR INFORMATION ONLY. PLEASE READ OUR TERMS AND
`CONDITIONS AND PRIVACY POLICY BEFORE USING THE SITE. ALL MATERIAL SUBJECT TO STRICTLY
`ENFORCED COPYRIGHT LAWS. © 2016 EUROMONEY INSTITUTIONAL INVESTOR PLC. FOR HELP PLEASE
`SEE OUR FAQ.
`
`v 1.0.26
`
`http://www.managingip.com/Blog/3516275/Kyle-Basss-success-rate-at-the-PTABan-updat...
`
`3/10/2016
`
`Fresenius Ex. 2023
`Bass et al. v. Fresenius Kabi USA, IPR2016-00254
`
`